ImmunityBio, Inc. (IBRX)
10.28
+1.00
(+10.83%)
USD |
NASDAQ |
Oct 02, 16:00
10.30
+0.02
(+0.15%)
After-Hours: 20:00
ImmunityBio EPS Diluted (Quarterly) : -0.2194 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2194 |
| March 31, 2026 | -0.6162 |
| December 31, 2025 | -0.0626 |
| September 30, 2025 | -0.071 |
| June 30, 2025 | -0.1042 |
| March 31, 2025 | -0.152 |
| December 31, 2024 | -0.0933 |
| September 30, 2024 | -0.1436 |
| June 30, 2024 | -0.1959 |
| March 31, 2024 | -0.1993 |
| December 31, 2023 | -0.3479 |
| September 30, 2023 | -0.1918 |
| June 30, 2023 | -0.3152 |
| March 31, 2023 | -0.2716 |
| December 31, 2022 | -0.2682 |
| September 30, 2022 | -0.2773 |
| June 30, 2022 | -0.2377 |
| March 31, 2022 | -0.2584 |
| December 31, 2021 | -0.2294 |
| September 30, 2021 | -0.2236 |
| June 30, 2021 | -0.2294 |
| March 31, 2021 | -0.208 |
| December 31, 2020 | -0.2955 |
| September 30, 2020 | -0.2012 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.2034 |
| March 31, 2020 | -0.1867 |
| December 31, 2019 | -0.1589 |
| September 30, 2019 | -0.1584 |
| June 30, 2019 | -0.1692 |
| March 31, 2019 | -0.2201 |
| December 31, 2018 | -0.219 |
| September 30, 2018 | -0.2984 |
| June 30, 2018 | -0.35 |
| March 31, 2018 | -0.3482 |
| December 31, 2017 | -0.31 |
| September 30, 2017 | -0.30 |
| June 30, 2017 | -0.29 |
| March 31, 2017 | -0.2985 |
| December 31, 2016 | -0.29 |
| September 30, 2016 | -0.39 |
| June 30, 2016 | -0.41 |
| March 31, 2016 | -0.38 |
| December 31, 2015 | -0.9455 |
| September 30, 2015 | -0.55 |
| June 30, 2015 | -2.380 |
| March 31, 2015 | -0.0578 |
| December 31, 2014 | -0.09 |
| March 31, 2014 | -0.0144 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Moderna, Inc. | -1.965 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -230.39M |
| Revenue (Quarterly) | 51.24M |
| Total Expenses (Quarterly) | 281.62M |
| Enterprise Value | 11.70B |
| Gross Profit Margin (Quarterly) | 90.82% |
| Profit Margin (Quarterly) | -449.6% |
| Earnings Yield | -9.42% |
| Normalized Earnings Yield | -5.293 |